“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions

About this episode

The episode discusses the impact of CNS disease on treatment decisions for EGFR-mutated non-small cell lung cancer.

Tackling central nervous system (CNS) disease in EGFR-mutated non-small cell lung cancer “is a huge problem, both from a quality-of-life perspective for patients and also from a longevity perspective,” explains Sid Devarakonda, MD, director of thoracic medical oncology at Swedish Cancer Institute in Seattle and clinical associate professor at Washington State University. He speaks with Aakash Desai, MD, MPH, associate director of the Phase 1 and Precision Oncology program at the University of Alabama at Birmingham, about how CNS metastases inform choices between regimens. Dr. Devarakonda also discusses how the recent U.S. Food and Drug Administration approval of subcutaneous amivantamab (Rybrevant Faspro) may change his approach. “[Y]ou still need to be comfortable managing some of the toxicities that still persist, even with the subcutaneous formulation, but it's terribly convenient from a practical perspective,” he notes. Dr. Desai and Dr. Devarakonda reported various financial relationships.

People in this episode

Guests: Sid Devarakonda, MD, Aakash Desai, MD, MPH

Topics covered

• CNS disease
• EGFR-mutated NSCLC
• treatment decisions
• quality of life
• FDA approval
• oncology

Keywords

• CNS disease
• EGFR mutation
• NSCLC
• treatment regimens
• FDA approval
• amivantamab
• oncology

Mentioned in this episode

Organizations: Swedish Cancer Institute, Washington State University, University of Alabama at Birmingham

Products: subcutaneous amivantamab (Rybrevant Faspro)

More episodes of Oncology News Central Peer-Spectives

• “Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care · April 29, 2026 · 11 min
• New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · April 21, 2026 · 9 min
• Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic · April 17, 2026 · 12 min
• Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care · April 2, 2026 · 14 min
• Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC · December 18, 2025 · 12 min
• “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC · December 16, 2025 · 13 min